Enzon returns rights to transplantation product to Fresenius Biotech

By Ted A. Knutson

Washington, Jan. 6 - Enzon Pharmaceuticals, Inc. announced Friday it is returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG.

ATG-Fresenius S is a polyclonal antibody preparation used for T-lymphocyte suppression to prevent organ graft rejection in organ transplant patients.

The companies are committed to working together to assure a smooth transition for the current ongoing clinical trial for ATG-Fresenius S.

Enzon said its decision to return full rights to Fresenius Biotech was based on its ongoing efforts to redirect its research and development investments to projects strategically aligned with its business objectives, including an increasing focus on cancer and adjacent therapeutic areas.

Enzon is a Bridgewater, N.J.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.